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ABSTRACT
Background
In 2000, Ontario, Canada, initiated a universal influenza immunization program (UIIP) to
provide free influenza vaccines for the entire population aged 6 mo or older. Influenza
immunization increased more rapidly in younger age groups in Ontario compared to other
Canadian provinces, which all maintained targeted immunization programs. We evaluated the
effect of Ontario’s UIIP on influenza-associated mortality, hospitalizations, emergency depart-
ment (ED) use, and visits to doctors’ offices.
Methods and Findings
Mortality and hospitalization data from 1997 to 2004 for all ten Canadian provinces were
obtained from national datasets. Physician billing claims for visits to EDs and doctors’ offices
were obtained from provincial administrative datasets for four provinces with comprehensive
data. Since outcomes coded as influenza are known to underestimate the true burden of
influenza, we studied more broadly defined conditions. Hospitalizations, ED use, doctors’ office
visits for pneumonia and influenza, and all-cause mortality from 1997 to 2004 were modelled
using Poisson regression, controlling for age, sex, province, influenza surveillance data, and
temporal trends, and used to estimate the expected baseline outcome rates in the absence of
influenza activity. The primary outcome was then defined as influenza-associated events, or the
difference between the observed events and the expected baseline events. Changes in
influenza-associated outcome rates before and after UIIP introduction in Ontario were
compared to the corresponding changes in other provinces. After UIIP introduction, influenza-
associated mortality decreased more in Ontario (relative rate [RR] ¼ 0.26) than in other
provinces (RR ¼ 0.43) (ratio of RRs ¼ 0.61, p ¼ 0.002). Similar differences between Ontario and
other provinces were observed for influenza-associated hospitalizations (RR¼0.25 versus 0.44,
ratio of RRs¼0.58, p , 0.001), ED use (RR¼0.31 versus 0.69, ratio of RRs¼0.45, p , 0.001), and
doctors’ office visits (RR ¼ 0.21 versus 0.52, ratio of RRs ¼ 0.41, p , 0.001). Sensitivity analyses
were carried out to assess consistency, specificity, and the presence of a dose-response
relationship. Limitations of this study include the ecological study design, the nonspecific
outcomes, difficulty in modeling baseline events, data quality and availability, and the inability
to control for potentially important confounders.
Conclusions
Compared to targeted programs in other provinces, introduction of universal vaccination in
Ontario in 2000 was associated with relative reductions in influenza-associated mortality and
health care use. The results of this large-scale natural experiment suggest that universal
vaccination may be an effective public health measure for reducing the annual burden of
influenza.
The Editors’ Summary of this article follows the references.
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Annual epidemics of inﬂuenza continue to cause world-
wide morbidity, mortality, and societal disruption. When
there is good match to circulating strains, inﬂuenza vaccines
are generally efﬁcacious and cost-effective for most age
groups [1–5]. However, some recent studies have questioned
the validity of the nonexperimental evidence for inﬂuenza
vaccine effectiveness in the elderly [6–9]. Efforts to reduce the
impact of inﬂuenza have mainly involved targeted inﬂuenza
immunization programs, which aim to vaccinate those at high
risk of complications from inﬂuenza infection and their
contacts [10,11].
In October 2000, the Canadian province of Ontario
initiated the world’s ﬁrst large-scale universal inﬂuenza
immunization program (UIIP) to provide free inﬂuenza
vaccinations for the entire population  6 mo of age [12].
Supporters have argued that universal programs have several
beneﬁts: increased numbers of people directly protected
from inﬂuenza by vaccination; possible indirect protection
(i.e., protection extending to nonvaccinated individuals)
arising from vaccinating greater proportions of the popula-
tion; and having vaccine procurement and delivery systems
in place for an inﬂuenza pandemic [13]. Critics have argued
that uncertainties surrounding both the effectiveness and the
cost-effectiveness of vaccinating healthy adults and children
may not justify the costs of implementing such programs
[14].
Ontario was the lone Canadian province to implement
UIIP; other provinces maintained targeted programs. Cana-
dian vaccination programs traditionally involve centralized
vaccine procurement by provincial governments with pub-
licly insured local delivery to high risk individuals and their
close contacts/care providers. Vaccine is delivered in health
care settings by nurses or physicians, or in community
settings through public health departments. High risk
individuals include seniors aged  65 y, individuals with
chronic medical conditions, children aged 6–23 mo (since
2004), and pregnant women (since 2007) [11]. UIIP introduc-
tion in Ontario entailed expansion of prior vaccination
activities, with local variations in delivery. Vaccine delivery
settings include physician ofﬁces, hospitals, schools, work-
places, pharmacies, community centres, and shopping malls.
The program also includes extensive media campaigns
promoting the availability and beneﬁts of free inﬂuenza
vaccinations.
Our earlier work found that universal vaccination was
associated with an overall incremental increase in vaccine
uptake in the household population aged  12 y of 9
percentage points (24- versus 15-percentage-point increase
in Ontario versus other provinces) between 1996–1997 and
2005 [15]. For those ,65 y, greater increases over time were
observed in Ontario compared to other provinces, whereas
lesser increases were observed in Ontario compared to other
provinces for those  85 y. All age groups in Ontario
maintained higher uptake rates compared to corresponding
age groups in other provinces throughout the study period.
In this study, we evaluated the effect of Ontario’s UIIP on
mortality, hospitalizations, emergency department (ED) use,
and doctors’ ofﬁce visits compared to targeted programs in
other Canadian provinces.
Methods
Study Population and Setting
This study included the population of the ten Canadian
provinces from 1997 to 2004 who were eligible for universal,
publicly insured health care services. Ethics approval was
obtained from the Sunnybrook Health Sciences Centre
Research Ethics Board, Toronto, Ontario.
Study Design
We used a pre-/post-intervention study design with
concurrent controls to assess the effect of Ontario’s UIIP
on inﬂuenza-associated mortality and health care use.
Although ecological studies do not permit inference to
individuals [16], this design was appropriate to evaluate the
impact of a population-level vaccination program on
population outcomes rather than the effect of vaccination
on individual outcomes.
Data Sources
Mortality data were obtained from Statistics Canada’s
Mortality Database, a national vital statistics dataset.
Hospitalization data were obtained from Statistics Cana-
da’s Hospital Morbidity Database, a national discharge
abstract dataset.
Physician services data were obtained from the following
provinces: Ontario, Quebec, Alberta, and Manitoba. These
provinces account for approximately 76% of the Canadian
population and were selected because of availability of
comprehensive data on physician services.
Annual population estimates were obtained from Statistics
Canada.
Vaccination rate data were obtained from the 1996–1997
cycle of the National Population Health Survey (NPHS) and
the 2000–2001, 2003, and 2005 cycles of the Canadian
Community Health Survey (CCHS). Conducted by Statistics
Canada using telephone and in-person interviews, these
surveys covered the household population aged  12 y but
excluded members of the Canadian Forces, Indian reserves,
and some remote areas, and those living in institutions. The
surveys had response rates of between 79% and 85%; details
have been described previously [15,17–21].
Outcomes
Inﬂuenza outcomes are difﬁcult to quantify because
inﬂuenza infections are typically not conﬁrmed. Since out-
comes coded as inﬂuenza are known to underestimate the
true burden of inﬂuenza, we studied more broadly deﬁned
conditions. These mortality and health care utilization
outcomes vary according to a cyclical ‘‘baseline’’ function
with winter peaks and summer troughs, but typically exhibit
spikes during periods of inﬂuenza virus activity [22,23]. Our
primary outcome was deﬁned as inﬂuenza-associated out-
comes, measured as the difference between observed events
and expected baseline events during inﬂuenza seasons. This
outcome reﬂects the excess number of events that occur
because of inﬂuenza activity beyond what would be expected
from background (baseline) rates. We chose this as our
primary outcome because it is only these excess events that
might be mitigated by a vaccination program.
For our primary mortality outcome, we included all deaths
between 24 August 1997 and 14 August 2004 (primary study
period comprising seven 52-wk periods).
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480–487, ICD-10-CA J10-J18) hospitalizations to acute care
facilities during the study period, excluding admissions of
nonresidents, transfers between institutions, and readmis-
sions within 1 wk of discharge. Although discharge abstracts
list up to 16 diagnoses, we used the ﬁrst ﬁve codes to capture
cases where inﬂuenza may have precipitated another con-
dition requiring hospitalization (e.g., congestive heart failure)
as well as nosocomial spread of inﬂuenza, while limiting the
potential effects of differential coding practices between
provinces and over time [24].
To assess ED use and visits to doctors’ ofﬁces, we included
all physician claims in ED and ofﬁce settings during the study
period for P&I. We included only one service claim per
patient per physician per day, and where possible, we
excluded claims that were associated with vaccination service
codes (i.e., a visit to receive inﬂuenza vaccination).
National Viral Surveillance Data
Respiratory virus detections. A national network of
hospital and provincial laboratories submit weekly reports
of numbers of tests performed (using viral culture or direct
antigen detection) and numbers of positive tests for inﬂuenza
A, inﬂuenza B, and respiratory syncytial virus (RSV) to the
Public Health Agency of Canada. The four Atlantic provinces
were grouped owing to small numbers of specimens tested.
Predominance of inﬂuenza subtype A(H3N2). A subset of
laboratories report further case-speciﬁc data including
subtype. Since A(H3N2)-predominant seasons have histor-
ically been more severe than A(H1N1)- and/or B-predominant
seasons [23], these data were used to measure the proportion
of the season’s subtyped isolates that were inﬂuenza subtype
A(H3N2) in each province and season (Table S1). This
variable was necessary because weekly subtype-speciﬁc data
were not available for the study period. Predominance of
A(H3N2) was generally consistent across provinces.
Vaccine antigenic match. A subset of viral isolates is sent to
Canada’s National Microbiology Laboratory for strain char-
acterization. The sample was assumed to represent the
distribution of strains for all inﬂuenza viruses circulating in
the population. The percentage of circulating strains that did
not match vaccine strains was calculated for each province
and season (percent mismatch) (Table S1).
Periods of Peak Influenza Activity
Periods of peak inﬂuenza activity were deﬁned separately
for each province and year, starting when the weekly
percentage of tests positive for inﬂuenza was greater than
10% and ending when the percentage fell below that
threshold for 2 consecutive wk (mean period duration ¼ 11
wk) (Table S1).
Statistical Analysis
We estimated inﬂuenza-associated events using a two-step
procedure. We ﬁrst ran multivariate regression models to
estimate weekly events as a function of population and
inﬂuenza season factors, and used this model to generate an
expected baseline representing the pattern of events occur-
ring in the absence of inﬂuenza. We then computed
inﬂuenza-associated events as the difference between the
number of observed events and expected baseline events
during periods of inﬂuenza activity.
In the ﬁrst step, we ran separate Poisson regression models
for each outcome, according to province and age group (,5,
5–19, 20–49 [,50 for mortality], 50–64, 65–74, 75–84, 85þ y)
[25]. We aggregated event counts by week and sex within
province-age group combinations. The dependent variable
was the weekly event count for males and females, and the
offset parameter was the province-age group-sex population.
Models controlled for sex; viral surveillance for inﬂuenza A,
inﬂuenza B, and RSV; the seasonal percentage of A(H3N2)
isolates; the percentage of mismatched strains; linear and
quadratic terms to model annual trends; and sine and cosine
terms with periods of 1 y to model seasonal ﬂuctuations, as in
previous studies [26,27]. To account for ﬂuctuations in health
service delivery during Christmas and post-Christmas holiday
periods, categorical terms were included in the health care
use models for these time periods. The model terms are
outlined in Text S1. The expected baseline was generated by
setting the inﬂuenza-related variables in the model (i.e.,
weekly percentage of tests positive for inﬂuenza A and B,
seasonal percentage of A[H3N2] isolates) to zero as these were
the terms that tracked inﬂuenza season peaks [26,27]. We
incorporated variance overdispersion in the estimates of all
standard errors (SE) to account for clustering of outcomes
within weekly strata since outcomes to individuals within
these strata may not be independent.
Weekly inﬂuenza-associated events were subsequently
computed as the difference between the number of observed
events and expected baseline events during periods of peak
inﬂuenza activity, where expected counts were based on the
adjusted Poisson models (Figure S1). These weekly estimates
were aggregated to produce annual estimates. Overall and
age-speciﬁc mean annual rates of inﬂuenza-associated out-
comes were calculated for the periods before and after
introduction of UIIP (pre-2000 versus post-2000), separately
for Ontario and the other provinces combined.
Pre- and post-UIIP inﬂuenza-associated event rates were
compared by dividing the adjusted postintervention rates by
the preinterventionratestoproducerelativerates (RR) ofUIIP
effect separately for Ontario and the other provinces com-
bined. The standard error of ln(RR) was computed assuming a
Poisson distribution for the overall counts and incorporating
the variance of the predicted baseline events [28]. The pre-/
post-RRs for Ontario and other provinces combined were
compared using the z-test and expressed as a ratio.
Model ﬁt was evaluated by examining the standardized
Pearson residuals for outlying points and secular trends. We
also evaluated the presence of inﬂuential provinces by
removing them individually from the model and reestimating
the UIIP effect. Although the model did not optimally ﬁt the
extreme, short-lived spikes that occurred during the peaks of
the inﬂuenza season, the ﬁt during the remainder of the
season was reasonable. We used the Durbin-Watson d-statistic
to test for autocorrelation in the residuals, both including
and excluding these inﬂuenza season spikes, averaging the
correlations across province- and age group-speciﬁc models.
Analyses were performed using SAS 9.1 (SAS Institute). All
statistical tests were computed at the 5% level of signiﬁcance
and were two sided.
Sensitivity Analyses
To conﬁrm the robustness of the ﬁndings, several
sensitivity analyses were conducted.
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ﬁndings, we used a 5% threshold for deﬁning periods of peak
inﬂuenza activity, leading to longer periods. We also lagged
inﬂuenza and RSV activity forward or backward by 1 wk, in
case of delays in viral testing or onset of serious illnesses (i.e.,
reports of positive tests and illness onset consistently
occurring in different weeks).
To increase the number of inﬂuenza seasons in the study,
we included data from the 1993–1994 to 1996–1997 inﬂuenza
seasons, but this analysis excluded data from Quebec and the
Atlantic provinces because prior to 1997–1998, the former
did not report the number of tests performed, preventing
calculation of weekly percentages of tests positive, and the
latter performed too few tests (,25/wk during inﬂuenza
season periods) to permit reliable calculation of percentages
of tests positive.
As another test of consistency, we restricted the analysis to
seasons in which A(H3N2) detections accounted for greater
than 50% of the total isolates (A[H3N2]-predominant
seasons).
For hospitalizations, we repeated the primary analysis
using all 16 codes (any-listed) and using only the ﬁrst code
(primary-listed).
Tests of effect ampliﬁcation. For mortality, we examined
deaths from respiratory and circulatory (R&C) conditions as a
more speciﬁc outcome for inﬂuenza. Deaths from P&I were
not assessed because of the small numbers of events at the
province- and age-speciﬁc level, and because of a sharp
decrease in P&I deaths coinciding with ICD-10 introduction
in 2000 that is known to be a coding artifact [29].
The 2003–2004 inﬂuenza season was noteworthy for the
emergence of the novel A/Fujian strain that accounted for
92% of the characterized isolates in Canada but was not
included in that season’s vaccine [30]. Since it was expected
that vaccine efﬁcacy would be reduced for that year, analyses
were repeated excluding that season to assess the impact of
universal vaccination for post-UIIP seasons with better
vaccine match. We conducted another analysis that excluded
all poor match seasons during the study period (i.e., the 1997–
1998 A/Sydney season and the 2003–2004 A/Fujian season).
Tests of effect attenuation. For the health care use
outcomes, we examined the effect of UIIP on less speciﬁc
outcomes. We examined hospitalizations for all respiratory
conditions (ICD-9-CM 460–519, ICD-10-CA J00-J99), and for
ED use and ofﬁce visits, we examined selected respiratory
conditions (composite of P&I, acute respiratory diseases
[ARD] [ICD-9 460–466], otitis media [OM] [ICD-9 381–383]
among those  50 y, and chronic obstructive pulmonary
disease [COPD] [ICD-9 490–492, 496] among those aged  20
y) [31,32]. Higher-order sine and cosine terms were used in
these models to achieve better ﬁt to the observed seasonal
variation in outcomes.
Data for the 2004–2005 season were available for hospital-
izations, so a sensitivity analysis adding that year to the study
period was performed. For that season, 35% of characterized
isolates were A/California and 4% were B/Hong Kong strains,
both of which were not included in that season’s vaccine,
although the A/Fujian component of the vaccine was believed
to provide partial protection against A/California [33].
Therefore, as a moderately poor match season, it was
expected to diminish the beneﬁts of the UIIP.
Tests of effect speciﬁcity. To assess the speciﬁcity of our
ﬁndings, we examined rates of all observed events, as opposed
to inﬂuenza-associated events, during the month of July, since
inﬂuenza viruses are not circulating in the summer and we
would not expect any inﬂuenza-associated events nor any
beneﬁt from inﬂuenza vaccination.
As another test of speciﬁcity, we examined the effect of the
UIIP on selected control conditions, by computing RRs for all
events during the month of February, when inﬂuenza viruses
are almost always circulating. For mortality, we used all non-
R&C conditions, for hospitalizations, we examined hernia,
and for ED use and ofﬁce visits, we considered lacerations.
Dose-response relationship. Regions with greater increases
in vaccination rates are expected to have greater decreases in
inﬂuenza-associated outcomes. To assess the presence of such
a relationship, we plotted age group-, province-, and out-
come-speciﬁc RRs for mean inﬂuenza-associated events
against absolute changes in vaccination rates. We used the
mean of the estimates from the three cycles of the Canadian
Community Health Survey as the measure of post-UIIP
vaccine uptake and the 1996–1997 National Population
Health Survey estimate as the measure of pre-UIIP vaccine
uptake. To match with the age groupings of the outcomes
data, we assumed that the vaccination rates of those aged 12
to 19 y applied to children as young as 5 y. We ﬁtted weighted
linear models separately by outcome and age group (,65 y
and  65 y), weighting by the inverse of the variance of the
RRs.
Results
Descriptive Results
Over the study period, mean annual outcome rates were
highest in older people and young children (Table 1). Plots of
weekly outcome rates over the study period for Ontario and
other provinces demonstrated seasonal trends with spikes
during periods of inﬂuenza activity (Figure 1).
Vaccination Rates
Between the pre-UIIP 1996–1997 estimate to the mean
post-UIIP vaccination rate, inﬂuenza vaccination rates for the
household population aged  12 y increased 20 percentage
points (18%–38%) for Ontario, compared to 11 percentage
points (13%–24%) for other provinces (p , 0.001) (Table 2).
For those ,65 y, the vaccination rate increases were greater
in Ontario than in other provinces, while for those  75 y, the
increase was smaller in Ontario. For all age groups, Ontario
always achieved higher vaccination rates than other prov-
inces.
Influenza-Associated Mortality and Health Care Use
After UIIP introduction, inﬂuenza-associated mortality for
the overall population decreased 74% in Ontario (RR ¼ 0.26,
95% conﬁdence interval [CI], 0.20–0.34) compared to 57% in
other provinces (RR¼0.43, 95% CI, 0.37–0.50) (ratio of RRs¼
0.61, p ¼ 0.002) (Table 3). In age-speciﬁc analyses, larger
mortality decreases in Ontario were found to be statistically
signiﬁcant only in those  85 y.
Overall, inﬂuenza-associated health care use decreased
more in Ontario than other provinces for hospitalizations
(RR¼0.25 versus 0.44, ratio of RRs¼0.58, p , 0.001), ED use
(RR ¼ 0.31 versus 0.70, ratio of RRs ¼ 0.45, p , 0.001), and
doctors’ ofﬁce visits (RR¼0.21 versus 0.53, ratio of RRs¼0.41,
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consistently observed in Ontario than other provinces for age
groups ,65 y. For seniors, greater decreases were observed in
Ontario than other provinces for hospitalizations among
those aged 65–84 y and for ED use among those 65–74 y.
There were no patterns detected in the standardized
residual plots against time, and no evidence of inﬂuential
provinces (Table S2). A greater than expected number of
outliers occurred during the 5 wk each year that inﬂuenza
activity was most intense, however, since the main purpose of
the model was to estimate the baseline rate in the absence of
inﬂuenza activity, these were not of major concern. The mean
ﬁrst order autocorrelation coefﬁcients (r) including (exclud-
ing) inﬂuenza spikes were 0.051 (0.039) for mortality, 0.255
(0.209) for hospitalizations, 0.398 (0.312) for ED use, and 0.548
(0.492) for doctors’ ofﬁce visits.
Sensitivity Analyses
The sensitivity analyses generally produced similar RR
ratios as the primary analysis for tests of consistency, smaller
RR ratios for tests of ampliﬁcation, larger RR ratios for tests
of attenuation, and RR ratios approximately equal to 1 for
tests of speciﬁcity, as expected (Table 4). Some exceptions
were noted, in particular mortality for R&C conditions, which
was not increased as anticipated; the secondary outcomes for
ED use and ofﬁce visits (selected respiratory conditions),
which were not attenuated as anticipated; and the analysis for
health care use including only A(H3N2) seasons resulted in
attenuation rather than consistency compared to the primary
analysis.
We found a dose-response relationship where greater
increases in vaccine uptake were associated with greater
decreases in inﬂuenza-associated outcomes for all health care
use outcomes for age groups ,65 y (all slopes negative, p ,
0.001) (Figure 2). For the elderly, the opposite relationship
was observed for mortality and hospitalizations, and no
relationship was noted for ED use and ofﬁce visits.
Discussion
After introduction of the world’s ﬁrst large-scale UIIP, we
found that inﬂuenza-associated mortality, hospitalizations,
ED use, and ofﬁce visits decreased more overall in Ontario
compared with other provinces. Age-speciﬁc analyses re-
vealed greater temporal drops in health care use in Ontario
compared to other provinces for younger age groups (i.e.,
ratios of pre-/post-RRs for Ontario versus other provinces
being closer to zero), with the gap between the RRs narrowing
with increasing age (i.e., ratios of RRs being closer to one).
This is consistent with the age-speciﬁc pattern for temporal
changes in vaccine uptake, with greater increases over time in
Ontario compared to other provinces for younger age groups
leading to greater expectations of beneﬁts from the UIIP.
However, for older age groups, in particular those  75 y,
greater incremental increases in vaccine uptake over time
were observed in other provinces compared to Ontario, yet
among all the outcomes, none of the RR ratios were greater
than one. This result is contrary to what one would expect
based on the assumption that greater increases in vaccine
uptake in those populations should have been associated with
greater decreases in outcome rates, and therefore suggests
that inﬂuenza vaccines may not be as effective in reducing
mortality and health care use in older people compared to
younger age groups.
Sensitivity analyses demonstrated consistency, speciﬁcity,
and the presence of a dose-response relationship between
temporal changes in vaccination rates and outcomes among
those ,65 y. A limited number of inconsistent results warrant
discussion. While the analysis restricted to A(H3N2)-predom-
inant seasons was expected to be a test of consistency, the
Table 1. Study Population Demographics and Mean Annual Event Rates over Study Period
Population Characteristics Study Population as of 1 July 2000 Mean Annual Event Rate per 100,000
All-Cause Mortality P&I
31,000 Percentage Hospitalizations ED Use Office Visits
Overall (10 provinces) — 30,591 100.0 717 390 882 3,504
Sex Female 15,445 50.5 694 366 861 3,745
Male 15,146 49.5 741 415 903 3,258
Age group (y) ,5 1,782 5.8 — 827 2,599 8,137
5–19 6,161 20.1 — 98 561 3,176
20–49 13,956 45.6 89
b 93 456 2,530
50–64 4,842 15.8 604 313 685 3,334
65–74 2,144 7.0 1,993 982 1,451 4,611
75–84 1,299 4.2 5,181 2,346 3,013 6,343
 85 406 1.3 15,100 4,747 5,771 9,080
Province Atlantic provinces
a 2,349 7.7 826 484 — —
Quebec 7,357 24.0 738 335 871 3,410
Ontario 11,685 38.2 695 376 914 3,637
Manitoba 1,147 3.8 853 537 414 3,444
Saskatchewan 1,008 3.3 585 408 — —
Alberta 3,005 9.8 882 651 961 3,240
British Columbia 4,039 13.2 700 358 — —
aAtlantic provinces: Newfoundland and Labrador, Nova Scotia, New Brunswick, Prince Edward Island
b0–49 y
doi:10.1371/journal.pmed.0050211.t001
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attenuation. This was likely because that analysis over-
weighted the inﬂuence of the 2003–2004 poor match season
by excluding the 2000–2001 and 2002–2003 non-A(H3N2)-
predominant seasons. Other unexpected results were the lack
of attenuation when examining the less speciﬁc secondary
outcomes for ED use and ofﬁce visits. This may have been
because the selected conditions are nearly as speciﬁc to
inﬂuenza as the primary outcome. Another inconsistency was
the lack of ampliﬁcation for the supposedly more speciﬁc
secondary outcome for mortality, respiratory, and circulatory
conditions. This lack of ampliﬁcation may be because R&C
mortality accounts for the bulk of the mortality from all
causes [26,34]. Regardless, the totality of these results suggest
that introduction of universal inﬂuenza vaccination in
Ontario has been associated with incremental beneﬁts in
terms of mortality and health care use compared to targeted
programs.
A previous study reported that UIIP introduction did not
lead to reduced inﬂuenza incidence [35], but used numbers of
laboratory-conﬁrmed cases as the outcome. Their negative
ﬁnding may have been a result of ascertainment bias arising
from a 10-fold increase in testing for inﬂuenza over the study
period [36].
Although many studies have found that for years with good
vaccine match, inﬂuenza vaccines are effective in preventing
hospitalizations and mortality in the elderly [2,3], the true
extent of vaccine effectiveness versus the effects of healthy
user biases has been the subject of much recent debate [6–9].
This study does not resolve that debate, however, the ﬁndings
suggest that in elderly populations, increasing vaccination
levels were not associated with decreases in inﬂuenza-
associated outcomes, and may have even been associated
with increased risk of mortality and hospitalizations. Poten-
tial explanations include immune senescence, or a decline in
immune responsiveness with advancing age [37–40], and
uncontrolled confounding. In working age adults, the
effectiveness of inﬂuenza vaccines for preventing inﬂuenza
infection and health care use is less controversial, and the
results from this study are consistent with this literature [4,5].
While previous studies have failed to demonstrate reductions
in hospitalizations among working age adults [41,42] and in
health care use among children [5], the ﬁndings from this
study suggest that increasing population-level vaccine uptake
in these age groups may be associated with substantial
reductions in these outcomes.
Despite universal availability of publicly insured health
care services, enhanced access to free inﬂuenza vaccines in
Ontario since 2000, and extensive media communications,
only an estimated average of 38% of the overall household
population reported receiving them during the post-UIIP
introduction period. Although vaccine uptake was higher in
older age groups (e.g., approximately 80% among those  75
y), it is uncertain that levels required for appreciable herd
immunity effects were obtained in the overall population,
particularly in younger age groups. Several studies have
claimed the existence of indirect beneﬁts arising from
vaccinating children, including a report on the impact of
vaccinating a community’s children on illness rates in the
adult population during the 1968 pandemic [43], a retro-
spective ecological analysis of a mass vaccination program for
schoolchildren and trends in seniors’ mortality in Japan [44],
Figure 1. Study Outcome Rates over the Study Period Demonstrating
Year-to-Year Variability in Mortality and Health Care Use, Temporal
Correlation with Ontario Influenza Viral Surveillance Data, and Increasing
Influenza Vaccination Rates Demonstrating Greater Increases in Ontario
Compared to Other Provinces Combined
Event rates (from top to bottom) for doctors’ office visits, ED use,
hospitalizations, and mortality (grey lines are for Ontario and black lines
are for other provinces combined) are expressed as rates per 100,000 on
the upper sections of the vertical axis. Viral surveillance data (grey
shaded areas) are expressed as the weekly percentage of tests positive
on the lower section of the vertical axis. Vaccination rates for the
household population aged  12 y (grey vertical bars are for Ontario and
black vertical bars are for other provinces combined) are expressed as
the percentage of the population vaccinated on the lower section of the
vertical axis. The horizontal axis represents time. The black vertical line
represents UIIP introduction.
doi:10.1371/journal.pmed.0050211.g001
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Universal Influenza Immunizationand a clinical trial that reported decreased rates of visits for
acute respiratory infections among adults after vaccinating
children with live-attenuated inﬂuenza vaccines [45]. Fur-
thermore, a modeling study of the potential effects of
vaccinating children on outcomes in the population sug-
gested that increasing vaccination rates of children from 20%
to 40% would lead to approximately 50% reductions in cases
of inﬂuenza, hospitalizations, and deaths [46]. In Ontario,
vaccination rates among those aged 12 to 19 y increased from
16% to 31% over the study period, while in other provinces,
rates increased from 6% to 11%. We observed more than
50% reductions in both inﬂuenza-associated mortality and
health care use over the study period among seniors in both
Ontario and other provinces. The bulk of these decreases are
likely attributable to less severe inﬂuenza seasons across
Canada in the postintervention period, but the larger
observed decreases in mortality for seniors aged  85 y,
hospitalizations for seniors aged 65–84 y, and ED use for
those aged 65–74 y in Ontario compared to other provinces
may be compatible with some indirect beneﬁts as previously
posited [46]. Unfortunately, this study does not permit
determination of the direct versus indirect beneﬁts of
universal vaccination.
Strengths of the study include the unique opportunity for a
‘‘natural experiment’’ and the fact that size of the popula-
tions of Ontario and the other provinces combined are
comparable. We addressed most of the criteria outlined
recently in a framework for addressing residual bias by
Simonsen et al., including: the selection of more speciﬁc
outcomes for the primary study outcomes (with the exception
of all-cause mortality) and the use of consistent modeling
techniques and laboratory surveillance data to estimate
inﬂuenza-associated events to reduce the potential dilution
of beneﬁts from universal vaccination that might arise from
employing all inﬂuenza season-associated events as the
outcome measure (end-point speciﬁcity); the sensitivity
analyses with poor match seasons excluded (vaccine match);
and the inclusion of events only during periods of peak
inﬂuenza activity and the sensitivity analysis using a summer
period (seasonality) [8]. Lastly, it is notable that the results are
consistent across three distinct outcomes (hospitalizations,
Table 2. Influenza Vaccination Rates over Time for Ontario and Other Provinces
Age
Group
Province Influenza Vaccination Rates p-Value*
1996–
1997
2000–
2001
2003 2005 Mean
Post-UIIP
a
Change
(Percentage
Points)
b
Percent 95%
CI
Percent 95%
CI
Percent 95%
CI
Percent 95%
CI
Percent 95%
CI
Percent 95%
CI
Overall Ontario 18 (18–19) 36 (35–37) 35 (34–36) 42 (42–43) 38 (37–38) 20 (19–20) ,0.001
Other
provinces
13 (12–13) 21 (20–22) 23 (22–23) 28 (28–29) 24 (24–24) 11 (10–12)
Atlantic
provinces
c
16 (14–17) 19 (18–20) 24 (24–25) 31 (30–32) 25 (24–25) 9 (7–10)
Quebec 8 (7–9) 18 (17–20) 20 (19–21) 25 (24–26) 21 (20–22) 13 (12–14)
Manitoba 14 (13–16) 22 (19–25) 20 (19–21) 28 (27–30) 23 (22–25) 9 (7–10)
Saskatchewan 13 (11–15) 19 (17–21) 24 (22–25) 28 (27–30) 24 (23–25) 10 (8–13)
Alberta 15 (15–16) 23 (21–25) 23 (22–24) 28 (27–29) 25 (24–26) 9 (8–10)
British
Columbia
17 (15–19) 26 (24–28) 27 (26–28) 33 (32–34) 29 (28–29) 11 (9–13)
12–19 y Ontario 16 (14–17) 29 (25–32) 28 (26–30) 37 (35–38) 31 (30–33) 15 (13–17) ,0.001
Other
provinces
6 (4–7) 9 (8–11) 10 (9–11) 14 (13–15) 11 (10–12) 5 (4–7)
20–49 y Ontario 8 (8–8) 27 (25–28) 23 (22–24) 30 (29–31) 27 (26–27) 19 (18–20) ,0.001
Other
provinces
6 (5–6) 12 (11–13) 13 (12–13) 18 (17–19) 14 (14–15) 9 (8–9)
50–64 y Ontario 21 (19–22) 42 (39–45) 45 (44–47) 54 (52–55) 47 (46–48) 26 (25–28) ,0.001
Other
provinces
15 (13–16) 23 (21–24) 29 (28–30) 35 (34–36) 29 (28–30) 14 (12–16)
65–74 y Ontario 54 (52–56) 69 (65–74) 71 (69–72) 73 (71–75) 71 (69–73) 17 (14–19) 0.86
Other
provinces
42 (39–46) 58 (55–61) 59 (57–60) 62 (61–63) 59 (58–61) 17 (13–21)
75–84 y Ontario 70 (67–72) 79 (74–83) 80 (78–82) 84 (82–85) 81 (79–82) 11 (8–14) 0.048
Other
provinces
54 (49–59) 71 (68–74) 68 (67–70) 73 (72–75) 71 (69–72) 17 (12–22)
 85 y Ontario 67 (61–73) 73 (63–84) 78 (74–83) 82 (77–86) 78 (74–82) 11 (3–18) 0.01
Other
provinces
44 (33–55) 71 (64–77) 71 (67–74) 76 (73–78) 72 (70–75) 28 (17–40)
aUIIP in Ontario.
bChange represents absolute percentage point difference between mean of the 2000–2001, 2003, and 2005 rates (post-UIIP) and the 1996–1997 rate (pre-UIIP).
cAtlantic provinces: Newfoundland and Labrador, Nova Scotia, New Brunswick, Prince Edward Island.
*p-Value for difference between the change over time in Ontario and other provinces combined (z-test).
doi:10.1371/journal.pmed.0050211.t002
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Universal Influenza ImmunizationED use, and ofﬁce visits), reducing the likelihood of spurious
ﬁndings attributable to data quality or other biases.
This study has a number of limitations. Individual-level
vaccination and outcome data were not available, necessitat-
ing an ecological study. However, use of this design is
appropriate for assessing the public health impact of a
population-wide intervention. As with other inﬂuenza studies
using health databases, the selected outcomes are nonspeciﬁc
and may be due to causes other than inﬂuenza, but the
strategies described above partly address this issue. The
quality and reliability of the outcome data over time, for
multiple jurisdictions, and across different classiﬁcation
systems (i.e., ICD-9 versus ICD-10) remain uncertain. The
validity of statistical models to estimate inﬂuenza-associated
events is limited by uncertainty of their accuracy, in spite of
our best efforts to achieve optimal model ﬁt. Laboratory viral
surveillance data are potentially susceptible to ascertainment
and reporting biases; the weekly proportion of tests positive
is felt to be the most robust measure of viral activity. Another
drawback of the study is that no vaccination rate data are
available for those ,12 y of age, an age group that
experiences particularly high rates of less severe inﬂuenza-
associated outcomes, or for institutionalized seniors, a group
that experiences higher rates of more severe outcomes.
Relatively high residual autocorrelation was likely due to the
difﬁculty in modeling a baseline inﬂuenza rate that did not
display purely cyclical behaviour despite inclusion of higher
order Fourier series terms; however, it suggests the possibility
of residual confounding due to season-speciﬁc factors such as
temperature or relative humidity. We were also not able to
include other potential confounders such as strain-speciﬁc
inﬂuenza surveillance data, prevalence of individual comor-
bidities, socioeconomic status, smoking rates, polysaccharide
or conjugated pneumococcal vaccination, antiviral medica-
tion use, and provincial health care system capacity, but we
have no reason to believe that these factors changed more
over time in Ontario compared to other provinces. For
example, pneumococcal vaccination of children has been
shown to reduce rates of pneumonia-related admissions in
older age groups [47,48] and might have contributed to
temporal changes in health care use for pneumonia, but
Ontario’s infant pneumococcal vaccination program was
introduced in January 2005, subsequent to the introduction
of pneumococcal vaccination programs in four other
provinces (September 2002 in Alberta, September 2003 in
British Columbia, October 2004 in Manitoba, and December
2004 in Quebec) (personal correspondence, A.-M. Frescura,
Public Health Agency of Canada). Therefore the greater
Table 3. Effect of UIIP on Influenza-Associated Mortality and Health Care Use Rates
Mortality and
Health Care Use
Age
Groups (y)
Mean Annual Influenza-Associated Event Rates (per 100,000) Ratio of
Ontario/
Other RRs
p
Value* Ontario Other Provinces Combined
Pre-2000 Post-2000 Post- Versus
Pre-RR (95% CI)
Pre-2000 Post-2000 Post- Versus
Pre-RR (95% CI)
Mortality All ages 14.8 3.9 0.26 (0.20–0.34) 16.1 6.9 0.43 (0.37–0.50) 0.61 0.002
,50 0.8 0.4 0.42 (0.13–1.42) 0.6 0.5 0.81 (0.28–2.34) 0.52 0.43
50–64 3.9 1.3 0.34 (0.06–2.02) 5.1 0.3 0.07 (0–23.46) 4.96 0.61
65–74 24.7 6.2 0.25 (0.09–0.70) 33.0 11.8 0.36 (0.21–0.61) 0.71 0.55
75–84 126.5 28.4 0.22 (0.14–0.36) 144.9 44.7 0.31 (0.23–0.41) 0.73 0.25
 85 562.8 134.3 0.24 (0.17–0.33) 525.4 255.8 0.49 (0.41–0.58) 0.49 ,0.001
Hospitalizations All ages 33.4 8.5 0.25 (0.23–0.28) 44.9 19.8 0.44 (0.42–0.46) 0.58 ,0.001
,5 44.5 23.6 0.53 (0.41–0.68) 44.3 59.9 1.35 (1.14–1.60) 0.39 ,0.001
5–19 2.1 1.3 0.63 (0.29–1.39) 2.0 5.0 2.56 (1.42–4.61) 0.25 0.005
20–49 6.0 1.2 0.21 (0.13–0.32) 10.5 5.9 0.56 (0.50–0.63) 0.37 ,0.001
50–64 25.4 2.0 0.08 (0.03–0.18) 44.4 15.8 0.36 (0.32–0.40) 0.22 ,0.001
65–74 88.8 15.2 0.17 (0.12–0.23) 134.6 39.1 0.29 (0.26–0.33) 0.59 0.002
75–84 258.8 57.2 0.22 (0.19–0.26) 318.6 93.2 0.29 (0.27–0.32) 0.76 0.006
 85 564.6 188.5 0.33 (0.29–0.39) 621.9 240.2 0.39 (0.35–0.43) 0.86 0.12
ED use All ages 139.6 43.6 0.31 (0.30–0.32) 125.0 85.9 0.69 (0.67–0.70) 0.45 ,0.001
,5 267.9 149.6 0.56 (0.51–0.61) 134.2 214.9 1.60 (1.43–1.79) 0.35 ,0.001
5–19 93.8 48.4 0.52 (0.48–0.55) 54.5 98.5 1.81 (1.68–1.94) 0.29 ,0.001
20–49 88.3 22.8 0.26 (0.24–0.28) 94.9 70.4 0.74 (0.72–0.77) 0.35 ,0.001
50–64 131.8 17.0 0.13 (0.11–0.15) 145.4 54.4 0.37 (0.35–0.40) 0.34 ,0.001
65–74 215.9 48.7 0.23 (0.20–0.26) 213.4 66.1 0.31 (0.28–0.34) 0.73 ,0.001
75–84 431.1 107.0 0.25 (0.22–0.28) 423.7 115.6 0.27 (0.25–0.30) 0.91 0.26
 85 853.1 308.4 0.36 (0.32–0.41) 732.2 303.0 0.41 (0.37–0.46) 0.87 0.10
Doctors’
office visits
All ages 813.6 173.0 0.21 (0.21–0.22) 587.7 306.2 0.52 (0.51–0.53) 0.41 ,0.001
,5 1,007.0 368.5 0.37 (0.35–0.39) 479.8 596.6 1.24 (1.16–1.33) 0.29 ,0.001
5–19 637.4 274.9 0.43 (0.42–0.44) 430.2 481.7 1.12 (1.09–1.15) 0.39 ,0.001
20–49 705.0 121.4 0.17 (0.17–0.18) 586.0 286.5 0.49 (0.48–0.50) 0.35 ,0.001
50–64 935.7 87.3 0.09 (0.09–0.10) 787.7 207.3 0.26 (0.25–0.27) 0.35 ,0.001
65–74 928.5 120.9 0.13 (0.12–0.14) 605.5 89.3 0.15 (0.13–0.17) 0.88 0.14
75–84 1440.1 245.5 0.17 (0.16–0.18) 720.9 109.3 0.15 (0.13–0.18) 1.12 0.16
 85 2,610.1 614.7 0.24 (0.22–0.25) 835.9 164.5 0.02 (0.17–0.23) 1.20 0.06
*p-Value for comparison between post- versus pre-RRs for Ontario and other provinces combined (z-test).
doi:10.1371/journal.pmed.0050211.t003
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Universal Influenza Immunizationdrops in inﬂuenza-associated outcomes observed in Ontario
after 2000 are unlikely to be attributable to pneumococcal
vaccination. Because of the observational nature of our study,
we cannot rule out the possibility of ‘‘healthy population’’
bias (i.e., healthier populations are more likely to get
vaccinated and have better outcomes), but our study design
and various tests of speciﬁcity support the absence of such a
bias. Most of the limitations arise from the necessity of using
existing health data. As we are not aware of other data or
approaches that can resolve these limitations, we believe this
study represents the best possible evaluation of a real-world
natural experiment that Ontario’s unique strategy to offer
inﬂuenza vaccination to the entire population represents.
Despite these limitations, this study provides suggestive
evidence of the population-based effectiveness of universal
vaccination programs using inactivated inﬂuenza vaccines. It
is not possible to deﬁnitively declare superiority of universal
programs over targeted programs, as the ﬁndings from this
study may not generalize to other settings. But by reducing
ﬁnancial barriers and increasing awareness and accessibility,
universal vaccination may bea ne f f e c t i v es t r a t e g yf o r
increasing a population’s protection against inﬂuenza. Future
studies to develop more immunogenic inﬂuenza vaccines, to
test novel strategies for further increasing vaccine uptake,
and to examine the cost-effectiveness of universal inﬂuenza
vaccination may be valuable.
Supporting Information
Figure S1. Estimating Inﬂuenza-Associated Events, Using P&I
Hospitalizations for Ontario Females  85 y as an Example
The left vertical axis represents hospitalization rate per 100,000. The
horizontal axis represents time. The solid black line represents
observed hospitalizations, the dashed black line represents baseline
hospitalizations in the hypothetical absence of inﬂuenza, and the
black vertical bars represent inﬂuenza-associated hospitalizations
(observed hospitalizations minus baseline hospitalizations). Viral
surveillance data (grey shaded areas) are expressed as the weekly
percentage of tests positive on the right vertical axis. The grey dashed
vertical lines denote periods of peak inﬂuenza activity.
Found at doi:10.1371/journal.pmed.0050211.sg001 (539 KB PPT).
Table S1. Duration of Periods of Peak Inﬂuenza Activity, Inﬂuenza
A(H3N2) Predominance, and Vaccine Antigenic Mismatch between
Circulating and Vaccine Strains, by Inﬂuenza Season and Province
Found at doi:10.1371/journal.pmed.0050211.st001 (97 KB DOC).
Table S2. Analysis to Evaluate the Presence of Inﬂuential Provinces
by Removing Them Individually from the Model
Found at doi:10.1371/journal.pmed.0050211.st002 (74 KB DOC).
Text S1. Description of the Multivariate Poisson Regression Model
Found at doi:10.1371/journal.pmed.0050211.sd001 (43 KB DOC).
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Figure 2. Sensitivity Analysis to Assess the Presence of a Dose-Response Relationship in Age Groups Older (A) and Younger (B) than 65 y for (from Left
to Right) Mortality [(A) only], Hospitalizations, ED Use, and Doctors’ Office Visits
The vertical axis represents the age group-, province-, and outcome-specific post- versus pre-2000 RRs. The horizontal axis represents the absolute post-
versus pre-2000 change in influenza vaccination rates (%). The bubble sizes represent the inverse of the variances of the post- versus pre-2000 RRs. The
p-values correspond to the significance of the estimates for the slope of the lines from weighted linear regression models (t-tests).
doi:10.1371/journal.pmed.0050211.g002
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Universal Influenza ImmunizationEditors’ Summary
Background. Seasonal outbreaks (epidemics) of influenza—a viral
disease of the nose, throat, and airways—affect millions of people and
kill about 500,000 individuals every year. These epidemics occur because
of ‘‘antigenic drift’’: small but frequent changes in the viral proteins to
which the human immune system responds mean that an immune
response produced one year by exposure to an influenza virus provides
only partial protection against influenza the next year. Immunization can
boost this natural immunity and reduce a person’s chances of catching
influenza. That is, an injection of killed influenza viruses can be used to
prime the immune system so that it responds quickly and efficiently
when exposed to live virus. However, because of antigenic drift, for
influenza immunization to be effective, it has to be repeated annually
with a vaccine that contains the major circulating strains of the influenza
virus.
Why Was This Study Done? Public-health organizations recommend
targeted vaccination programs, so that elderly people, infants, and
chronically ill individuals—the people most likely to die from pneumonia
and other complications of influenza—receive annual influenza vacci-
nation. Some experts argue, however, that universal vaccination might
provide populations with better protection from influenza, both directly
by increasing the number of vaccinated people and indirectly through
‘‘herd immunity,’’ which occurs when a high proportion of the
population is immune to an infectious disease, so that even unvacci-
nated people are unlikely to become infected (because infected people
rarely come into contact with susceptible people). In this study, the
researchers compare the effects of the world’s first free universal
influenza immunization program (UIIP), which started in 2000 in the
Canadian province of Ontario, on influenza-associated deaths and health
care use with the effects of targeted vaccine programs on the same
outcomes elsewhere in Canada.
What Did the Researchers Do and Find? Using national records, the
researchers collected data on influenza vaccination, on all deaths, and on
hospitalizations for pneumonia and influenza in all Canadian provinces
between 1997 and 2004. They also collected data on emergency
department and doctors’ office visits for pneumonia and influenza for
Ontario, Quebec, Alberta, and Manitoba. They then used a mathematical
model to estimate the baseline rates for these outcomes in the absence
of influenza activity, and from these calculated weekly rates for deaths
and health care use specifically resulting from influenza. In 1996–1997,
18% of the population was vaccinated against influenza in Ontario
whereas in the other provinces combined the vaccination rate was 13%.
On average, since 2000—the year in which UIIP was introduced in
Ontario—vaccination rates have risen to 38% and 24% in Ontario and the
other provinces, respectively. Since the introduction of UIIP, the
researchers report, influenza-associated deaths have decreased by 74%
in Ontario but by only 57% in the other provinces combined. Influenza-
associated use of health care facilities has also decreased more in Ontario
than in the other provinces over the same period.
What Do These Findings Mean? These findings are limited by some
aspects of the study design. For example, they depend on the accuracy
of the assumptions made when calculating events due specifically to
influenza, and on the availability and accuracy of vaccination and clinical
outcome data. In addition, it is possible that influenza-associated deaths
and health care use may have decreased more in Ontario than in the
other Canadian provinces because of some unrecognized health care
changes specific to Ontario but unrelated to the introduction of universal
influenza vaccination. Nevertheless, these findings indicate that,
compared to the targeted vaccination programs in the other Canadian
provinces, the Ontarian UIIP is associated with reductions in influenza-
associated deaths and health care use, particularly in people younger
than 65 years old. This effect is seen at a level of vaccination unlikely to
produce herd immunity so might be more marked if the uptake of
vaccination could be further increased. Thus, although it is possible that
Canada is a special case, these findings suggest that universal influenza
vaccination might be an effective way to reduce the global burden of
influenza.
Additional Information. Please access these Web sites via the online
version of this summary at http://dx.doi.org/10.1371/journal.pmed.
0050211.
  Read the related PLoS Medicine Perspective by Ce ´cile Viboud and Mark
Miller
  A related PLoS Medicine Research Article by Carline van den Dool and
colleagues is also available
  The Ontario Ministry of Health provides information on its universal
influenza immunization program (in English and French)
  The World Health Organization provides information on influenza and
on influenza vaccines (in several languages)
  The US Centers for Disease Control and Prevention provide informa-
tion for patients and professionals on all aspects of influenza (in
English and Spanish)
  MedlinePlus provides a list of links to other information about
influenza (in English and Spanish)
  The UK National Health Service provides information about the science
of immunization, including a simple explanatory animation of
immunity
PLoS Medicine | www.plosmedicine.org October 2008 | Volume 5 | Issue 10 | e211 1452
Universal Influenza Immunization